Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?

Current molecular medicine - 1 Jan 2014

Baranova E V, Asselbergs F W, de Boer A, Maitland-van der Zee A H

Abstract excerpt

Coumarin derivates are oral anticoagulants commonly prescribed for treatment and prevention of thromboembolism. Due to a small therapeutic index and large inter- and intrapatient differences in dose requirements, treatment with coumarins is challenging, particularly in its starting phase. Extensive evidence suggests that common genetic variants in CYP2C9 and VKORC1 genes together with a number of clinical factors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coumarins
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Share to Thromboembolism

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 25109798
DOI: 10.2174/1566524014666140811114906

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?PMID 25109798Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Semantic proximity Read ↗

Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.Semantic proximity Read ↗

Genotype-guided coumarin dosing: where are we now and where do we need to go next?Semantic proximity Read ↗

Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Warfarin pharmacogenomics: current best evidence.Semantic proximity Read ↗

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Patients benefit from genetics-guided coumarin anticoagulant therapy.Semantic proximity Read ↗

Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.